The description of oncogenic mutations (e.g., EGFR mutations) and the introduction of new therapeutics directly targeting these molecular changes (e.g., EGFR TKIs) have changed the therapeutic strategies in lung cancer treatment. The gene discussed is EGFR; the disease is lung carcinoma.